首页> 外文期刊>Urology >In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/mL.
【24h】

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/mL.

机译:在前列腺癌患者中,人腺激肽释放酶与游离PSA的比例改善了总PSA 4到10 ng / mL的诊断“灰色区域”内前列腺癌与良性增生之间的区别。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: Human glandular kallikrein (hK2) possesses approximately 80% structure identity with prostate-specific antigen (PSA). Moreover, messenger ribonucleic acid for hK2 and for PSA is expressed in both benign and malignant prostatic tissue. We investigated whether the hK2 serum measurement may improve the detection of prostate cancer (PCa) in patients with total PSA of 4 to 10 ng/mL (diagnostic "gray zone"). METHODS: Blood samples were obtained from 90 consecutive male patients with lower urinary tract symptoms and total PSA values of 4 to 10 ng/mL. Eighty-one patients underwent transurethral resection of the prostate and 6 radical prostatectomy. The patients were divided into two groups: I, patients with PCa (n = 20) and II, patients with benign prostatic hyperplasia (BPH) (n = 70). An "in-house" immunofluorometric assay with analytical sensitivity of 0.01 ng/mL and the functional sensitivity of 0.05 ng/mL (at this level the mean coefficient of variation, calculated from the precision profile based on the assays of serum samples, was less than 20%) was used to determine serum hK2 concentrations. Total PSA, free PSA (ProStatus), and PSA complexed to alpha1-antichymotrypsin (PSA-ACT) were also measured. Free/total PSA, hK2/total PSA, and hK2/free PSA ratios were calculated. RESULTS: The serum hK2 could be detected in all samples and in 76 (84.4%) of 90 samples (PCa, n = 18; BPH, n = 58) at given functional sensitivity level. For these cases the median concentration of hK2 was 0.135 ng/mL in PCa and 0.09 ng/mL in BPH (P < 0.1). The median hK2/total PSA ratio was 2% for PCa and 1.6% for BPH (P < 0.2). The median free/total PSA ratio was 0.122 for PCa and 0.215 for BPH (P < 0.0008) and the hK2/free PSA ratio was 0.139 for PCa and 0.075 for BPH (P < 0.000003). At a 7.2% cutoff, the specificity of hK2/free PSA ratio was 48.2% at 100% sensitivity and increased to 60.3% at 94.4% sensitivity level (the area under the receiver operating characteristic curve was 0.86). In comparison, the free/total PSA ratio at a 25.2% cutoff had a sensitivity of 94.4% and a specificity of 27.6% (area under the curve = 0.76). CONCLUSIONS: hK2 was detected in all sera with total PSA values of 4 to 10 ng/mL. Of particular clinical interest is the finding that the hK2/free PSA ratio had a better specificity without loss of sensitivity for PCa than total PSA or the PSA free/total ratio within the range of 4 to 10 ng/mL total PSA. hK2 in combination with free PSA may offer a new diagnostic means for PCa detection.
机译:目的:人腺激肽释放酶(hK2)与前列腺特异性抗原(PSA)具有大约80%的结构同一性。此外,hK2和PSA的信使核糖核酸在良性和恶性前列腺组织中均表达。我们调查了hK2血清测量是否可以改善总PSA为4至10 ng / mL(诊断为“灰色区”)的患者中前列腺癌(PCa)的检测。方法:从90名连续的下尿路症状的男性患者中采集血样,总PSA值为4至10 ng / mL。八十一例患者接受了经尿道前列腺电切术和六例前列腺癌根治术。患者分为两组:I,PCa患者(n = 20)和II,良性前列腺增生(BPH)患者(n = 70)。 “内部”免疫荧光测定法的分析灵敏度为0.01 ng / mL,功能灵敏度为0.05 ng / mL(在此水平下,根据基于血清样品测定的精密度曲线计算出的平均变异系数较小大于20%)用于确定血清hK2浓度。还测量了总PSA,游离PSA(ProStatus)和与α1-抗胰凝乳蛋白酶复合的PSA(PSA-ACT)。计算自由/总PSA,hK2 /总PSA和hK2 /自由PSA比率。结果:在给定的功能敏感性水平下,在所有样品中以及在90个样品(PCa,n = 18; BPH,n = 58)中的76个(84.4%)中均可检测到血清hK2。对于这些情况,PCa中hK2的中位浓度为0.135 ng / mL,BPH中hK2的中位浓度为0.09 ng / mL(P <0.1)。 PCa的中值hK2 /总PSA比率为2%,BPH的中值hK2 /总PSA比率为1.6%(P <0.2)。 PCa的中位游离/总PSA比为0.122,BPH为0.215(P <0.0008),PCa的hK2 /游离PSA比为0.139,BPH为0.075(P <0.000003)。截止值为7.2%时,hK2 /游离PSA比的特异性在100%灵敏度下为48.2%,在94.4%灵敏度水平下增加至60.3%(接收器工作特性曲线下的面积为0.86)。相比之下,截止到25.2%时,游离/总PSA比率的灵敏度为94.4%,特异性为27.6%(曲线下的面积= 0.76)。结论:在所有血清中均检测到hK2,总PSA值为4至10 ng / mL。特别令人感兴趣的临床发现是,与总PSA或总PSA在4 ng / mL到10 ng / mL范围内相比,hK2 /游离PSA比具有更好的特异性而对PCa的敏感性没有损失。 hK2与免费的PSA结合可能为PCa检测提供一种新的诊断手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号